Piper Sandler downgraded Tango Therapeutics (TNGX) to Neutral from Overweight with a price target of $24, up from $16.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics price target raised to $55 from $28 at Leerink
- Tango Therapeutics price target raised to $33 from $19 at Wedbush
- Tango Therapeutics downgraded to Hold from Buy at Jefferies
- Tango Therapeutics Reshapes Board Amid Late-Stage Progress
- Tango Therapeutics reports Q1 EPS (32c), consensus (31c)